Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 9/20 | 0.40 |
| ▸ | MMP1 | P03956 | 5/20 | 0.39 |
| ▸ | MMP2 | P08253 | 4/20 | 0.39 |
| ▸ | MMP9 | P14780 | 4/20 | 0.39 |
| ▸ | MMP3 | P08254 | 3/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 2/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080824 | 0.90 | MMP13 (0.48) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7078100 | 0.82 | MMP2 (0.44) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7075454 | 0.81 | POLB (0.46) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7075243 | 0.80 | MMP13 (0.43) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7078207 | 0.79 | MMP2 (0.53) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7079056 | 0.77 | MMP2 (0.65) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7078652 | 0.72 | MMP1 (0.49) | MMP1MMP2MMP9MMP3MMP8 | |
| SCHEMBL7077896 | 0.69 | MMP2 (0.60) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL7507734 | 0.65 | MMP2 (0.47) | MMP13MMP1MMP2MMP9MMP3 | |
| SCHEMBL6578094 | 0.65 | MMP2 (0.65) | MMP13MMP1MMP2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | MMP13 1/4885MMP1 16/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.